CoChat
Cited by 194

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

Non-invasive Breath Analysis of Pulmonary Nodules

Open access
Peled, Nir, Hakim, Meggie, Bunn, Paul A., Miller, York E., Kennedy, Timothy C., Mattei, Jane, Mitchell, John D., Hirsch, Fred R., Haick, Hossam · 2012 · Journal of Thoracic Oncology

Abstract

Introduction: The search for non-invasive diagnostic methods of lung cancer (LC) has led to new avenues of research, including the exploration of the exhaled breath. Previous studies have shown that LC can, in principle, be detected through exhaled-breath analysis. This study evaluated the potential of exhaled-breath analysis for the distinction of benign and malignant pulmonary nodules (PNs). Methods: Breath samples were taken from 72 patients with PNs in a prospective trial. Profiles of volatile organic compounds were determined by (1) gas chromatography/mass spectrometry (GC-MS) combined with solid-phase microextraction and (2) a chemical nanoarray. Results: Fifty-three PNs were malignant and 19 were benign with similar smoking histories and comorbidities. Nodule size (mean ± SD) was 2.7 ± 1.7 versus 1.6 ± 1.3 cm (p = 0.004), respectively. Within the malignant group, 47 were non–small-cell lung cancer and six were small-cell lung cancer. Thirty patients had early-stage disease and 23 had advanced disease. Gas chromatography/mass spectrometry analysis identified a significantly higher concentration of 1-octene in the breath of LC, and the nanoarray distinguished significantly between benign versus malignant PNs (p < 0.0001; accuracy 88 ± 3%), between adeno- and squamous-cell carcinomas [LINE SEPARATOR](p < 0.0001; 88 ± 3%) and between early stage and advanced disease (p < 0.0001; 88 ± 2%). Conclusions: In this pilot study, breath analysis discriminated benign from malignant PNs in a high-risk cohort based on LC-related volatile organic compound profiles. Furthermore, it discriminated adeno- and squamous-cell carcinoma and between early versus advanced disease. Further studies are required to validate this noninvasive approach, using a larger cohort of patients with PNs detected by computed tomography.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1097/jto.0b013e3182637d5f

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

  • Reduced Lung-Cancer Mortality with Low-Dose Computed Tomographic Screening

    The National Lung Screening Trial Research Team (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1102873 · Cited by 11,064 · cited 1×

    “The National Lung Screening Trial demonstrated that LC screening by low-dose computed tomography (LDCT) scans reduced the LC mortality rate by 20%.(3) LDCT screening programs for LC are expected to be launched in many countries in the near future so that a dramatic increase in the detection of pulmonary nodules (PNs)…”
    Background
  • Cancer statistics, 2012

    Siegel, R., Naishadham, D., & Jemal, A. (2012) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20138 · Cited by 10,679

  • Cancer cell metabolism: warburg and beyond

    Hsu, P. P., & Sabatini, D. M. (2008) · Cell · doi:10.1016/j.cell.2008.08.021 · Cited by 2,452 · cited 1×

    “It would be reasonable to expect a higher quantity and variety of metabolites released by the SCLC, because SCLC cells are rapidly dividing cells that require more adenosine triphosphate, nucleotides, fatty acids, membrane lipids, and proteins.(30) This assumption is based on our previous report of pronounced differen…”
    Background

Cited by

See all 194

Metadata

Authors
Peled, N., Hakim, M., Bunn, P. A., Miller, Y. E., Kennedy, T. C., Mattei, J., Mitchell, J. D., Hirsch, F. R., & Haick, H.
Venue
Journal of Thoracic Oncology
Publisher
Elsevier BV
Published
2012-10
Volume
7
Issue
10
Pages
1528-1533
ISSN
1556-0864 (ISSN-L)
OpenAlex
W1998960474
Cited by
194
References
3
FWCI
8.55
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.